3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pain, Postoperative
3
Pain
2
Neoplasm Metastasis
2
Hematologic Neoplasms
2
Vesico-Ureteral Reflux
1
Ureteral Neoplasms
1
Supratentorial Neoplasms
1
Pain, Intractable
1
Nephrolithiasis
1
Neoplasms
1
Multiple Myeloma
1
Mucositis
1
Lymphoma
1
Liver Neoplasms
1
Leukemia
1
Leiomyoma
1
Kidney Neoplasms
1
Ileus
1
Chronic Pain
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Bone Marrow Failure Disorders
1
Anemia, Aplastic
1
Agnosia
1
Advanced Malignant Neoplasm
1
Interventions
durvalumab
13
Bevacizumab
11
Nivolumab
10
tremelimumab
7
pembrolizumab
6
lenvatinib
6
fludarabine
6
Cyclophosphamide
6
atezolizumab
4
Radiosurgery
4
Cisplatin
4
toripalimab
3
relatlimab
3
Magnetic Resonance Imaging
3
Ipilimumab
3
Gemcitabine
3
X-Rays
2
Standard of Care
2
Sorafenib
2
Riluzole
2
Radiotherapy
2
Photons
2
Patient Navigation
2
Lidocaine
2
Hepatectomy
2
Dexamethasone
2
Biopsy
2
trastuzumab deruxtecan
1
tocilizumab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Morphine
×
1 year
×
Clear all
NCT03715517
2026-02-05
SAFER-L
University of Manitoba
Phase NA
Recruiting
128 enrolled